Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $64.44

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has been assigned an average rating of "Buy" from the eleven ratings firms that are covering the firm, Marketbeat reports. Eleven investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $64.44.

A number of brokerages have recently issued reports on JSPR. BMO Capital Markets began coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an "outperform" rating and a $63.00 price target on the stock. Royal Bank of Canada cut their target price on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating on the stock in a research report on Thursday, January 9th. HC Wainwright cut their target price on Jasper Therapeutics from $60.00 to $40.00 and set a "buy" rating on the stock in a research report on Friday, January 10th. JMP Securities reissued a "market outperform" rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research report on Monday, January 6th. Finally, UBS Group assumed coverage on Jasper Therapeutics in a research report on Thursday, February 13th. They issued a "buy" rating and a $38.00 target price on the stock.

Institutional Investors Weigh In On Jasper Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers grew its position in Jasper Therapeutics by 12.6% during the 4th quarter. Rhumbline Advisers now owns 14,761 shares of the company's stock worth $316,000 after purchasing an additional 1,652 shares during the period. BNP Paribas Financial Markets grew its position in Jasper Therapeutics by 208.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock worth $47,000 after purchasing an additional 1,698 shares during the period. Barclays PLC grew its position in Jasper Therapeutics by 13.6% during the 4th quarter. Barclays PLC now owns 18,334 shares of the company's stock worth $392,000 after purchasing an additional 2,188 shares during the period. Wellington Management Group LLP grew its position in Jasper Therapeutics by 13.9% during the 4th quarter. Wellington Management Group LLP now owns 27,069 shares of the company's stock worth $579,000 after purchasing an additional 3,310 shares during the period. Finally, Fernwood Investment Management LLC grew its position in Jasper Therapeutics by 6.9% during the 3rd quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company's stock worth $995,000 after purchasing an additional 3,427 shares during the period. 79.85% of the stock is owned by institutional investors and hedge funds.

Jasper Therapeutics Trading Down 3.1 %

Shares of JSPR stock traded down $0.19 during trading hours on Thursday, reaching $5.97. 497,966 shares of the company's stock were exchanged, compared to its average volume of 427,668. The stock's 50 day moving average is $11.23 and its 200-day moving average is $17.13. The company has a market cap of $89.52 million, a price-to-earnings ratio of -1.26 and a beta of 2.11. Jasper Therapeutics has a fifty-two week low of $4.55 and a fifty-two week high of $31.01.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.